Investing in Psychedelics

Jeff Siegel and Simeon Schnapper recap the historic MAPS Psychedelics Conference in Denver, Colorado, which over 16,000 people attended. Simeon discusses the intersection of philanthropic and capital market fundraising, the surrealism of hobnobbing with industry players like John Gilmore, documentary filmmaker Lucy Walker, Governor Jared Polis, former Governor Rick Perry and Stanford's Gary Nolan, and the profundity and abundance of the insights into psychedelic medicine, in particular ibogaine. Simeon then touches on some challenges that were discussed at the conference, such as how to ensure reciprocity for the indigenous tribes who pioneered many psychedelics.

Simeon and Jeff are joined by journalist and drug legalization advocate, Nick Gillespie, editor at large of Reason magazine and the newest member of JLS' Advisory Board. In a far-reaching but deeply nuanced conversation, Simeon, Jeff and Nick discuss the end of the American Drug War, how the anti-prohibition movement is transcending traditional narratives of political ideology and partisanship, and what the future of the psychedelic medicine might look like from a healthcare and business perspective. Nick takes a holistic and historical approach, highlighting the lessons the psychedelic industry can learn from alcohol prohibition, cannabis legalization, Viagra, Covid-19 and the Civil Rights movement. Nick's key point: with anything to do with psychedelics, "the devil is in the details."

Simeon and Jeff discuss the swift rise of psychedelics in mainstream culture, as well as the potential pitfalls of celebrity endorsements. Topics include recent promotions from Mike Tyson and MMA fighters, UFC President Dana White committing funds to study the benefits and risks of psychedelics for athletes, and former adult-film star Mia Khalifa joining Red Light Holland as an advisor. Then Simeon and Jeff analyze the significance of the American Medical Association granting a Current Procedural Terminology (CPT) code to psychedelic therapies.

Simeon and Jeff discuss the cost-effectiveness of MDMA-assisted therapy, the legalization of psychedelic medicine in Saint Vincent and the Grenadines, and the passage of a psychedelics bill in Utah.

What's in store for 2022

Detroit decriminalizes psychedelics and understanding the value of companies developing the first protocols for psychedelic-assisted therapies.

Simeon and Jeff discuss psychedelics ETFs, Wesana Health (OTCBB: WSANF) (CSE: WESA), and destigmatizing plant medicine in Times Square.

Can psychedelics help smokers kick the habit? Early research from Johns Hopkins University indicates that it’s possible, and now Mydecine (NEO: MYCO) (OTCBB: MYCOF) is partnering with Johns Hopkins on a new smoking cessation study using the company’s own psilocbyin drug candidate. And a new Senate bill to decriminalize psychedelics is introduced.

Join Investing in Psychedelics each week as we discuss the latest news, announcements and trends that will help you take full advantage of what is now proving to be one of the most profitable and disruptive industries of the 21st century.

Why the decriminalization of psychedelics matters for investors. Can psychedelics end addiction? And Wesana (CSE: WESA) (OTCBB: WSNAF) is making big moves.